News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Volastra Therapeutics dosed the first patient in their Phase I/II clinical trial of VLS-1488
Photo from Volastra Therapeutics/LinkedIn
Nov 3, 2023, 12:06

Volastra Therapeutics dosed the first patient in their Phase I/II clinical trial of VLS-1488

Volastra Therapeutics shared on their LinkedIn page:

”We’ve dosed the first patient in our Phase I/II clinical trial of VLS-1488, our internally discovered KIF18A inhibiting drug designed to treat patients with advanced cancers characterized by high levels of chromosomal instability.”

For more information click here.
Source: Volastra Therapeutics/LinkedIn

cancer clinical trial KIF18A inhibition OncoDaily Oncology VLS-1488 Volastra Therapeutics
Special Coverage
Opinion
Feb 28, 2025, 18:34
Does Sunscreen Cause Cancer? Myths and Facts about Sunscreen and Cancer
Blog
Feb 28, 2025, 15:34
Cancer World welcomes their Co-Editors-in-Chief
Blog
Feb 28, 2025, 15:33
PTCy-based GVH disease prophylaxis for matched sibling donor - IACH
Blog
Feb 28, 2025, 15:25
NanCI: Connecting Scientists Gets New Features - Train at NCI
Blog
Feb 28, 2025, 15:22
Javier Cortes about value of global collaboration at EIOC 2024
Blog
Feb 28, 2025, 15:20
Dr. Tori Willard Early Career Award: Call for Proposals - SIOP
Blog
Feb 28, 2025, 15:13
Lucas’s journey with acute lymphoblastic leukemia - St. Baldrick's Foundation
Blog
Feb 28, 2025, 15:12
Catherine Alix-Panabières: Honored to welcome Key International Experts in Liquid Biopsy from 14 different countries
Blog
Feb 28, 2025, 15:02
Best registration rates for ESMO Breast 25 before 6 March
Blog
Feb 28, 2025, 14:50
Elvina Almuradova: The FDA has granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive mCRPC
Science
Feb 28, 2025, 14:43
Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors
Science
Feb 28, 2025, 14:37
Yan Leyfman: Promising Results for Sickle Cell Transplant